With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Subscribe To Our Newsletter & Stay Updated
